azane;dichloroplatinum

Base Information

• Chemical Name: azane;dichloroplatinum
• CAS No.: 14913-33-8
• Molecular Formula: Cl₂H₆N₂Pt
• Molecular Weight: 300.047
• Hs Code.: 28439000
• Wikidata: Q412415
• Mol file: 14913-33-8.mol

Synonyms:trans-DDP;trans-diamminedichloroplatinum II;trans-dichlorodiammineplatinum II;transplatin

Chemical Property of azane;dichloroplatinum

Chemical Property:

• Appearance/Colour: Yellow Powder or Crystal
• Melting Point: 340 °C (dec.)(lit.)
• PSA: 6.48000
• Density: 3.746 g/cm3
• LogP: 2.02430
• Storage Temp.: 2-8°C
• Water Solubility.: Soluble in dimethylsulfoxide and dimethylformamide. Slightly soluble in water.
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 0
• Exact Mass: 298.955598
• Heavy Atom Count: 5
• Complexity: 2.8

Purity/Quality:

99%, ^*data from raw suppliers

Transplatin ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T; Xn
• Hazard Codes: T,Xn
• Statements: 45-25-41-68-42/43-40-23/24/25
• Safety Statements: 53-26-39-45-36/37-24-23

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: N.N.Cl[Pt]Cl
• Recent ClinicalTrials: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
• Recent EU Clinical Trials: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
• Recent NIPH Clinical Trials: Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma
• Uses: Transplatin is the trans stereoisomer impurity of trans-Dichlorodiamineplatinum(II), an antineoplastic used in the treatment of sarcomas, some carcinomas, lymphomas, and germ cell tumors. Transplatin binds to DNA but does not exhibit the same useful pharmacological effect as its cis stereoisomer. Transplatin is the trans stereoisomer impurity of Cisplatin (C499500), an antineoplastic used in the treatment of sarcomas, some carcinomas, lymphomas, and germ cell tumors. Transplatin binds to DNA but does not exhibit the same useful pharmacological effect as its cis stereoisomer.

Technology Process of azane;dichloroplatinum

There total 115 articles about azane;dichloroplatinum which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 52.0%

cis-diaminediiodoplatinum(II) + potassium chloride → cisplatine (26035-31-4,14913-33-8,15663-27-1)

Guidance literature:

cis-diaminediiodoplatinum(II); With silver sulfate; In water; at 80 ℃;

potassium chloride; In water; at 80 ℃; for 0.333333h;

DOI:10.1021/jacs.9b10319

Reference yield:

ethacraplatin (847227-34-3) → cisplatine (26035-31-4,14913-33-8,15663-27-1) + ethacrynic acid (58-54-8)

Guidance literature:

With sodium L-ascorbate; In tetrahydrofuran; aq. phosphate buffer; dimethyl sulfoxide; at 20 ℃; pH=7.4; Kinetics;

DOI:10.1002/cmdc.201800105

Reference yield:

C13H18Cl4N2O5Pt → cisplatine (26035-31-4,14913-33-8,15663-27-1) + ethacrynic acid (58-54-8)

Guidance literature:

With sodium L-ascorbate; In aq. phosphate buffer; at 20 ℃; pH=7.4; Kinetics;

DOI:10.1002/cmdc.201800105

upstream raw materials:

platinum(II) chloride

ammine of zinc platinum(II) chloride

cis-diamminetetrachloroplatinum(IV)

Downstream raw materials:

K{PtaCl₃}*H₂O

trans-diamminetetrachloroplatinum(IV)

trans dithiocyanato diammine platinum (II)

triamminechloroplatinum(II) chloride

Refernces

Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery

10.1021/ja5038269

The study presents the development of a series of platinum(IV) prodrugs, specifically designed to enhance interaction with human serum albumin (HSA) for drug delivery purposes. The prodrugs were synthesized by asymmetrically functionalizing the axial ligands to mimic the features of a fatty acid, with the aim of improving cellular uptake and cytotoxicity. The lead compound, 4e, which has a hexadecyl chain, demonstrated a significant therapeutic potential due to its ability to form a tight, non-covalent complex with HSA (complex 7), enhancing its stability in blood and reducing the rate of reduction by ascorbate. The study involved platinum(IV) complexes with varying aliphatic tail lengths, including 4a, 4b, 4c, 4d, and 4e, which were used to investigate the impact of lipophilicity on cellular uptake and cytotoxicity. Other chemicals used included cisplatin as a reference compound, succinic anhydride, isocyanate reagents for the synthesis of the prodrugs, and ascorbate as a biological reductant to study the reduction of the Pt(IV) prodrugs. The purpose of these chemicals was to create a novel class of anticancer prodrugs with improved properties, such as enhanced stability, reduced side effects, and potentially increased efficacy.

(S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin: A Putative 5-HT_1A-Receptor Antagonist

10.1021/jm00168a002

The research explores the development and properties of alkylating organoselenones as potential antitumor agents. The study aims to investigate the potential of organoselenones for their high nucleophilic selectivity and their ability to act as biological alkylating agents, which could be useful in cancer treatment. The researchers synthesized various organoselenones and related compounds, including sulfone and aryl haloalkyl selenones (1-6), and tested their chemical kinetic parameters and antiproliferative activities. Key chemicals used in the research include 4-(4-nitrobenzyl)pyridine (NBP) as a model biologic nucleophile, and various nitrogen, sulfur, and selenium compounds for comparison. The study found that organoselenones exhibited desirable properties such as slowed reactivity compared to selenides, high selectivity, and short cross-linking distances similar to cisplatin. The results suggest that these organoselenones could be promising candidates for the development of new antitumor agents with improved selectivity and efficacy.

Design, synthesis, and cytotoxic evaluation of a new series of 3-substituted spiro[(dihydropyrazine-2,5-dione)-6,3′-(2′,3′- dihydrothieno[2,3-b]naphtho-4′,9′-dione)] derivatives

10.1021/jm0612158

The study investigates the development of a new series of spirodiketopiperazine derivatives for their cytotoxic potential against various human tumor cell lines. The researchers synthesized these compounds by condensing the 3-amino-3(ethoxycarbonyl)-2,3-dihydrothieno[2,3-b]naphtho-4,9-dione system with various amino acids, followed by intramolecular lactamization. The study evaluated the cytotoxic activity of these derivatives against MCF-7 human breast carcinoma and SW 620 human colon carcinoma cell lines, revealing that certain isomers derived from Proline (Pro), Cysteine (Cys), and Methionine (Met) exhibited cytotoxic potency comparable to or greater than that of doxorubicin. The study also explored the topoisomerase II inhibition activity and DNA-binding properties of these compounds. The results suggest that these derivatives could potentially circumvent multiple-drug resistance mechanisms and have significant cytotoxic effects on various tumor cell lines, including those resistant to doxorubicin and cisplatin.